| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0925-4439(96)00062-2 |
| P50 | author | Peter Riederer | Q7176599 |
| P2093 | author name string | Renate Müller | |
| Reinhard Schinzel | |||
| Gerald Münch | |||
| Anne M. Cunningham | |||
| Alan R. Hipkiss | |||
| Samantha Mayer | |||
| Arne Neumann | |||
| Jürgen Michaelis | |||
| P2860 | cites work | Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease | Q72582686 |
| Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa | Q27861105 | ||
| An agent cleaving glucose-derived protein crosslinks in vitro and in vivo | Q28285167 | ||
| Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline | Q28319359 | ||
| Neuritic plaque amyloid in Alzheimer's disease is highly racemized | Q34049047 | ||
| Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking | Q34180583 | ||
| Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes | Q34290612 | ||
| Retardation of the senescence of cultured human diploid fibroblasts by carnosine | Q34341446 | ||
| Advanced glycosylation: chemistry, biology, and implications for diabetes and aging | Q34351918 | ||
| Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease | Q34415666 | ||
| Protein fructosylation: fructose and the Maillard reaction | Q34728173 | ||
| Serum advanced glycosylation end products: a new class of uremic toxins? | Q40647352 | ||
| Cellular and molecular biology of Alzheimer's disease and animal models | Q40759701 | ||
| Normal and abnormal biology of the beta-amyloid precursor protein | Q40766055 | ||
| A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes | Q40779597 | ||
| Biochemistry of Alzheimer's disease amyloid plaques | Q40810047 | ||
| Natural histidine-containing dipeptide carnosine as a potent hydrophilic antioxidant with membrane stabilizing function. A biomedical aspect | Q40841777 | ||
| Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? | Q40918121 | ||
| Hydrogen peroxide mediates amyloid beta protein toxicity | Q41460857 | ||
| Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases | Q43828915 | ||
| Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state | Q44689258 | ||
| Complement gene expression in human brain: comparison between normal and Alzheimer disease cases | Q46033229 | ||
| Age as risk factor for sporadic dementia of the Alzheimer type? | Q48120495 | ||
| Activation of macrophages by Alzheimer beta amyloid peptide | Q48156863 | ||
| New Alzheimer's therapy suggested | Q48266215 | ||
| Alzheimer's disease. A glycation connection. | Q53205627 | ||
| Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. | Q53213016 | ||
| Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. | Q53311110 | ||
| The significance of the Maillard reaction in human physiology | Q67923745 | ||
| The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins | Q68859285 | ||
| Blood-brain glucose transfer: repression in chronic hyperglycemia | Q70185240 | ||
| Pathways of Formation of Glycoxidation Products during Glycation of Collagen | Q71786493 | ||
| Non‐enzymatic glycosylation of the dipeptide l‐carnosine, a potential anti‐protein‐cross‐linking agent | Q72035251 | ||
| Carnosine protects proteins against in vitro glycation and cross-linking | Q72114363 | ||
| Nonenzymatic glycation interferes with protein concentration determinations | Q72141075 | ||
| The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation | Q72232433 | ||
| Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction | Q72387391 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 17-29 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | BBA: Molecular Basis of Disease | Q15749547 |
| P1476 | title | Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide | |
| P478 | volume | 1360 |
| Q44198123 | Accumulation of imidazolone, pentosidine and N(epsilon)-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain |
| Q37800424 | Advanced glycation endproducts and their pathogenic roles in neurological disorders |
| Q43752090 | Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. |
| Q73138940 | Advanced glycation endproducts in ageing and Alzheimer's disease |
| Q35035514 | Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. |
| Q34534524 | Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress |
| Q45784169 | Aminoguanidine changes hippocampal expression of apoptosis-related genes, improves passive avoidance learning and memory in streptozotocin-induced diabetic rats. |
| Q48188316 | An immunochemical study on tau glycation in paired helical filaments |
| Q28534489 | Anti-aggregating effect of the naturally occurring dipeptide carnosine on aβ1-42 fibril formation |
| Q34313891 | Arsenosugar induced blood and brain oxidative stress, DNA damage and neurobehavioral impairments |
| Q30332310 | Carnosine promotes the heat denaturation of glycated protein. |
| Q73222113 | Carnosine protects against excitotoxic cell death independently of effects on reactive oxygen species |
| Q34615356 | Carnosine supplementation protects rat brain tissue against ethanol-induced oxidative stress |
| Q77321308 | Carnosine, a protective, anti-ageing peptide? |
| Q43685736 | Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups |
| Q43225017 | Carnosine: can understanding its actions on energy metabolism and protein homeostasis inform its therapeutic potential? |
| Q43013056 | Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. |
| Q38229613 | Chronic neuroinflammation in Alzheimer's disease: new perspectives on animal models and promising candidate drugs |
| Q57956891 | Copper(ii) and zinc(ii) dependent effects on Aβ42 aggregation: a CD, Th-T and SFM study |
| Q48517116 | Crosslinking of amyloid-beta peptide to brain acetylcholinesterase. |
| Q27648717 | Crystal structures of yeast beta-alanine synthase complexes reveal the mode of substrate binding and large scale domain closure movements |
| Q33475007 | Cytotoxicity of Maillard reaction products determined with a peptide spot library |
| Q30374807 | Differential effects of glycation on protein aggregation and amyloid formation. |
| Q44141439 | Effect of exogenous testosterone on oxidative status of the testes in adult male rats |
| Q43987557 | Effects of thermal denaturation on protein glycation |
| Q73416412 | Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine |
| Q36629895 | From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain |
| Q30393668 | Glycation in Demetalated Superoxide Dismutase 1 Prevents Amyloid Aggregation and Produces Cytotoxic Ages Adducts |
| Q38762228 | Glycation in Parkinson's disease and Alzheimer's disease |
| Q42828706 | Glycation of Wild-Type Apomyoglobin Induces Formation of Highly Cytotoxic Oligomeric Species |
| Q33573668 | Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide |
| Q39368611 | Impact of Non-Enzymatic Glycation in Neurodegenerative Diseases: Role of Natural Products in Prevention. |
| Q79185026 | Intervention against the Maillard reaction in vivo |
| Q48300482 | Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice. |
| Q35164047 | Involvement of Maillard reactions in Alzheimer disease |
| Q45345441 | Mechanisms of maturation and ageing of collagen |
| Q44298068 | Methylglyoxal-induced glycation affects protein topography |
| Q38417850 | Microfluidic-based non-enzymatic glycation enhances cross-linking of human scleral tissue compared to conventional soaking |
| Q44340602 | New insights into protein crosslinking via the Maillard reaction: structural requirements, the effect on enzyme function, and predicted efficacy of crosslinking inhibitors as anti-ageing therapeutics |
| Q44260190 | Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia |
| Q42536387 | Pluripotent protective effects of carnosine, a naturally occurring dipeptide |
| Q46723184 | Protective effect of carnosine during nitrosative stress in astroglial cell cultures |
| Q86446427 | Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-κB pathway |
| Q40337302 | Relation between different treatment modalities and genomic damage of end-stage renal failure patients |
| Q38161415 | The Janus face of PAMAM dendrimers used to potentially cure nonenzymatic modifications of biomacromolecules in metabolic disorders-a critical review of the pros and cons. |
| Q35847041 | The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease |
| Q28139932 | The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease |
| Q36622649 | The significance of the cholinergic system in the brain during aging and in Alzheimer's disease |
| Q45204753 | Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future |
Search more.